Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

Experimental Neurology

Volumn 203, Issue 2, 2007, Pages 293-301

  Perry, TracyAnn ^a   Holloway, Harold W ^a   Weerasuriya, Ananda ^b   Mouton, Peter R ^c   Duffy, Kara ^c   Mattison, Julie A ^c   Greig, Nigel H ^a  

^a Drug Design and Development Section   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Behavior; Diabetes; Exendin 4; GLP 1; Morphology; Neuropathy; Neuroprotection; Neurotrophic; Pyroxidine; Rat; Stereometry

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LONG ACTING DRUG; PYRIDOXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HISTOPATHOLOGY; INSULIN RELEASE; MALE; MORPHOMETRICS; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SECOND MESSENGER; SENSORY NEUROPATHY; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BODY WEIGHT; GANGLIA, SPINAL; GLUCAGON-LIKE PEPTIDE 1; MALE; MOLECULAR SEQUENCE DATA; MUSCLE TONUS; MUSCULOSKELETAL EQUILIBRIUM; NERVE DEGENERATION; NEURONS, AFFERENT; NEUROPROTECTIVE AGENTS; PEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRIDOXINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SCIATIC NERVE; VENOMS; VITAMINS;

EID: 33846501672     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.09.028     Document Type: Article

References (26)

1. Albin R.L., Albers J.W., Greenberg H.S., Townsend J.B., Lynn R.B., Burke Jr. J.M., and Alessi A.G. Acute sensory neuropathy-Neuronopathy from pyridoxine overdose. Neurology 37 (1987) 1729-1732
2. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., and Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9 (2003) 1173-1179
3. Estall J.L., and Drucker D.J. Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 12 (2006) 1731-1750
4. Goke R., Larsen P.J., Mikkelsen J.D., and Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7 (1995) 2294-2300
5. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J., Garant M.J., and Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42 (1999) 45-50
6. Greig N.H., Mattson M.P., Perry T., Chan S.L., Giordano T., Sambamurti K., Rogers J.T., Ovadia H., and Lahiri D.K. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann. N.Y. Acad. Sci. 1035 (2004) 290-315 (Dec)
7. Holst J.J. 2006, Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49, 253-260.
8. Krinke G.J., and Fitzgerald R.E. The pattern of pyridoxine-induced lesion: difference between the high and the low toxic level. Toxicology 49 (1988) 171-178
9. Kuntzer T., Antoine J.C., and Steck A.J. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 30 (2004) 255-268
10. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24 (2006) 1633-1642
11. Nakagawa A., Satake H., Nakabayashi H., Nishizawa M., Furuya K., Nakano S., Kigoshi T., Nakayama K., and Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 110 (2004) 36-43
12. Perry T., and Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol. Sci. 24 (2003) 377-383
13. Perry T., and Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 377-385
14. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., and Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300 (2002) 958-966
15. Perry T., Haughey N.J., Mattson M.P., Egan J.M., and Greig N.H. Protection and reversal of excitotoxic damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302 (2002) 1-8
16. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., and Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72 (2003) 603-612
17. Perry T.A., Weerasuriya A., Mouton P.R., Holloway H.W., and Greig N.H. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp. Neurol. 190 (2004) 133-144
18. Satoh F., Beak S.A., Small C.J., Falzon M., Ghatei M.A., Bloom S.R., and Smith D.M. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology 141 (2000) 1301-1309
19. Schaeppi U., and Krinke G. Pyridoxine neuropathy: correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6. Agents Actions 12 (1982) 575-582
20. Shughrue P.J., Lane M.V., and Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137 (1996) 5159-5162
21. Shukitt-Hale B., Mouzakis G., and Joseph J.A. Psychomotor and spatial memory performance in aging male Fischer 344 rats. Exp. Gerontol. 33 (1998) 615-624
22. Sima A.A. Pathological mechanisms involved in diabetic neuropathy: can we slow the process?. Curr. Opin. Investig. Drugs 7 (2006) 324-337
23. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
24. Wang Y., Perfetti R., Greig N.H., Holloway H.W., DeOre K.A., Montrose-Rafizadeh C., Elahi D., and Egan J.M. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 99 (1997) 2883-2889
25. Windebank A.J., Low P.A., Blexrud M.D., Schmelzer J.D., and Schaumburg H.H. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology 35 (1985) 1617-1622
26. Xu Y., Sladky J.T., and Brown M.J. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 39 (1989) 1077-1083